Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane and ubiquitin-like domain-containing protein 2 (TMUB2)
- Target
- TMUB2
- Molecular classification
- Protein coding gene, Membrane protein (predicted), Other (not classified as a receptor, ion channel, enzyme, transporter, etc.)
01
Overview
Transmembrane and ubiquitin-like domain-containing protein 2 (TMUB2) is a ubiquitously expressed human membrane protein encoded by the TMUB2 gene on chromosome 17q21.31. TMUB2 contains three transmembrane regions and is conserved across species. Its molecular weight is approximately 33.8 kDa, consisting of 321 amino acids in humans. The protein is predicted to participate in the ERAD pathway, which is involved in the degradation of misfolded proteins in the endoplasmic reticulum. TMUB2 has no confirmed biological or clinical functions as of 2025, and there are no approved drugs or biomarker uses associated with this protein. Its only known interactions are with Ubiquitin C (UBC) and potentially with BCL2L13, SGTA, and UBQLN1. TMUB1 is the only reported paralog. There is no current evidence to suggest direct involvement in diseases or therapeutic relevance.
- Other names
- TMUB2Transmembrane and ubiquitin-like domain containing 2HGNC:28459NCBI Gene:79089Ensembl:ENSG00000168591UniProt:Q71RG4GC17P039620GC17P042264GC17P038028
02
Mechanism of action
None known
03
Biological functions
Unknown; predicted to be involved in ERAD (endoplasmic-reticulum associated degradation) pathwayPossibly implicated in protein homeostasis related to ubiquitin signalingOther (function not yet elucidated)
04
Disease associations
None established or knownOther (no evidence for involvement in cancer, neurodegenerative diseases, or others)
05
Safety considerations
None documented; no known therapeutic interventions
06
Interacting drugs
None known
07
Biomarkers
None established
Beyond the preview
Go deeper on Transmembrane and ubiquitin-like domain-containing protein 2 (TMUB2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transmembrane and ubiquitin-like domain-containing protein 2 (TMUB2).